ArticleVirus evolution2025
SARS-CoV-2 CoCoPUTs: analyzing GISAID and NCBI data to obtain codon statistics, mutations, and free energy over a multiyear period.
Article in Virus evolution, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Inequities and global declines in SARS-CoV-2 genomic data availability hinder response to emerging variants.Npj viruses · 2026Review
- Temporal and gene-specific dynamics of codon usage evolution in SARS-CoV-2 genomes.BMC genomics · 2026Article
- Analysis of the Relationship Between the Charge Increment of the SARS-CoV-2 Spike Protein and Evolution.Viruses · 2025Article
- What Has SARS-CoV-2 Taught Us About Evolution?Cureus · 2025Review
- Is SARS-CoV-2 facing constraints in its adaptive evolution?Biomolecules & biomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
A consistent area of interest since the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been the sequence composition of the virus and how it has changed over time. Many resources have been developed for the storage and analysis of SARS-CoV-2 data, such as GISAID (Global Initiative on Sharing All Influenza Data), NCBI, Nextstrain, and outbreak.info. However, relatively little has been done to compile codon usage data, codon-level mutation data, and secondary structure data into a single database. Here, we assemble the aforementioned data and many additional virus attributes in a new database entitled SARS-CoV-2 CoCoPUTs. We begin with an overview of the composition and overlap between two of the largest sources of SARS-CoV-2 sequence data: GISAID and NCBI Virus (GenBank). We then evaluate different types of sequence curation strategies to reduce the dataset of millions of sequences to only one sequence per Pango lineage variant. We then performed specific analyses on the coding sequences (CDSs), including calculating codon usage, codon pair usage, dinucleotides, junction dinucleotides, mutations, GC content, effective number of codons (ENCs), and effective number of codon pairs (ENCPs). We have also performed whole-genome secondary RNA structure prediction calculations for each variant, using the LinearPartition software and modified selective 2'-hydroxyl acylation analyzed by primer extension (SHAPE) data that are available online. Finally, we compiled all the data into our resource, SARS-CoV-2 CoCoPUTs, and paired many of the resulting statistics with variant proportion data over time in order to derive trends in viral evolution. Although the overall codon usage of SARS-CoV-2 did not change drastically, in line with the previous literature on this subject, we did observe that while overall GC% content decreased, GC% of the third position in the codon was more positive relative to overall GC% content between February 2021 and July 2023. Over the same interval, we noted that both synonymous and nonsynonymous mutations increased in number, with nonsynonymous mutations outpacing synonymous mutations at a rate of 3:1. We noted that the predicted whole-genome secondary structures nearly all contained the previously described virus-activated inhibitor of translation (VAIT) stem loops, validating for the first time their existence in a whole-genome secondary structure prediction for many SARS-CoV-2 variants (as opposed to previous local secondary structure predictions). We also separately produced a synonymous mutation-deprived set of SARS-CoV-2 variant sequences and repeated the secondary structure calculations on this set. This revealed an interesting trend of reduced ensemble free energy compared to the unaltered variant structures, indicating that synonymous mutations play a role in increasing the free energy of viral RNA molecules. These data both validate previous studies describing increases in viral free energy in human viruses over time and indicate a possible role for synonymous mutations in viral biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.